added to the well × dilution factor of the virus used to infect the well in which the plaques 1 were enumerated [12] .
2 Evaluation of antiviral activities of Carragennan on WRL68 cell line 3 The cells were seeded into 24-well plates (1 × 105 cells per well) for 24 h at 37°C and 5% 4 CO2. JEV culture supernatant was separately added to the cells at an M.O.I. of 1, followed by 5 incubation for two h with gentle shaking every 15 min to achieve optimal virus-to-cell 6 contact. The cells were washed twice with phosphate-buffered saline (PBS) after removing 7 the virus culture supernatant. Subsequently, the new complete DMEM containing 25 µg/ml 8 of Carrageenan or heparin was added to the cultures and further incubated for 72 h. Viral 9 titers were evaluated using plaque formation assays. then removed, and the cells were washed three times with PBS to remove any residual virus.
7
Then, fresh complete DMEM was added, and the cultures were further incubated for 72 h at 1 8 37°C supplemented with 5% CO2. The viral titers of DENV2 and JEV suspension were then 1 9 determined via plaque formation assays. This assay was performed to show the ability of Carrageenan to inhibit DENV2 and JEV 2 2 entry into host cells. WRL68 cells were grown in 24-well plates (1 × 105 cells/well) for 24 h. Cell culture media were removed and the cells were then washed three times with PBS. New 2 4 media containing virus and the test compound (25 µg/ml) mixture were separately added and 2 5 6 the cells were incubated for one h at 4°C. Subsequently, the media was removed and the cells 1 were washed extensively with cold PBS to remove the unabsorbed virus. The cells were 2 overlaid with DMEM containing 1.1% methylcellulose and incubated for five days. Viral 3 titers were quantified by counting infectious centers.
4
Post-infection treatment 5 The cells were seeded in 24-well plates (1 × 105 cells/well) for 24 h. Cell culture media were 6 removed and the cells were then washed three times with PBS. New media containing virus 7 (M.O.I of 2) was added and incubated at 37°C with gentle shaking every 15 min for two h.
8
The virus was then removed by washing the cells twice with PBS followed by the addition of 9 new complete DMEM containing (25 µg/ml) of the test compound. The cells were then 1 0 incubated for 72 h. The viral titers of JEV were then determined by plaque formation assays. All assays were performed in triplicates, and the statistical analyses were performed using 1 9
GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA). P values <0.05 were 2 0 considered significant. The error bars are expressed as ± SD. The potential cytotoxicity effect of Carrageenan was evaluated using WRL68 cells and 2 4 heparin was employed as a positive control. The 50% cytotoxic concentration (CC50) was 2 5 higher than 200 µg/ml for both Carrageenan and heparin The maximal non-toxic dose 1 (MNTD) value was approximately 25 µg/ml and showed at least 95% cell viability.
2
Following this, all subsequent in vitro cell culture experiments were carried out using doses 3 of less than 25 µg/ml of the potential compounds ( Fig. 1A and 1B ). carrageenan or heparin showed approximately normal monolayer sheets with lessen CPE 1 1 (Fig. 2) . Then, the antiviral activity of carrageenan against JEV was investigated by plaque p.f.u./ml) as a positive control (t-test, P<0.01) as presented in Figure 3B . We then incubated 2 2 the WRL68 cells with JEV at 37°C for two h and subsequently treated the cells with the test carrageenansignificantly inhibited virus attachment to target cells that was similar to heparin.
1 4 (C) Post-infection treatment showed that the inhibitory effect of carrageenan against JEV was 1 significant but at lower extent compared to the antiviral activity against viral entry (t-test 2 p<0.01). Moreover, treatment with carrageenan also showed significant protective effects 3 which retained the viability of infected cells to more than 75% (t-test, p<0.01).
4
Carrageenan inhibited JEV in a dose-dependent manner 5 Our investigations showed Carrageenan increased inhibition potentials against JEV; we next 6 characterized the antiviral activity of Carrageenan against JEV using an ELISA-like cell-7 based assay (Fig. 4) . Our results demonstrated that Carrageenan inhibited JEV replication in 8 WRL68 cells in a dose-dependent manner. The 50% effective concentration (EC50) for 9
Carrageenan was approximately 15 µg/ml, which is similar to the positive control heparin 1 0 (Fig. 4) . The immunostaining experiment showed that the concentration level of virus 1 1 particles was considerably decreased after applying increased concentrations from 10 µg/ml 1 2
to 30 µg/ml of Carrageenan (Fig. 5) . was approximately 15 µg/ml which is approximately similar to the positive control heaprin. The fixed cells were treated with anti-JEV mouse antibodies and then treated with fluorescein 5 (FITC)-labeled goat anti-mouse IgG. The results showed that the inhibitory effects were 6 dependent on increasing concentrations of carrageenan. On the other hand, in the post-infection assay, Carrageenan showed lower but significant 1 3 antiviral activities towards JEV infection. It has been found that heparan sulphate (HS) is 1 4
involved in the first interaction with E glycoprotein to initiate a flavivirus multiplication 1 5
cycle in different types of vertebrate cells [21] . HS is a member of highly sulphated 1 6 glycosaminoglycans (GAGs), which is very abundant on the surface of most mammalian 1 7 cells and serves as a receptor for many microbial agents, including bacteria, parasites, and 1 8
viruses [22] . For DENV, the interaction with HS is unusual, owing to its specificity for a 1 9
highly sulphated form of HS [23] . Therefore, the polysaccharide, 2 0 curdlan sulphate showed a potential antiviral activity through interfering with the cellular Our studies also showed that Carrageenan exhibited differing levels of antiviral strength polysaccharides) [25, 26] . However, it is difficult for researchers to accurately characterize 7 and purify a particular type of polysaccharide from the extracts of natural sources, which also 8 remains as an inherent limitation in this study. To this end, further research is still needed to 9 elucidate the exact mechanism of inhibition by Carrageenan and its association with the JEV present, and future of Japanese encephalitis. Emerg Infect Dis, 15(1), 1-7. medicinal plants extracts against dengue virus using dengue NS2B-NS3 protease assay. Tropical 1 1
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